25 Nov

Respiri to present today at MST Financial Forum

Respiri Limited ¦ ABN 98 009 234 173 ¦ Suite 1, Level 9, 432 St Kida Road, MELBOURE VIC 300 4 ¦ Page | 1 ASX ANNOUNCEMENT 2 5 November 202 1 Respiri to present at MST Financial Life sciences & Biotech Foru m Respiri Limited (ASX:RSH)(“Respiri” or the “Company ” ) , an eHealth SaaS Company supporting respiratory health management , is pleased to announce that CEO Marjan Mikel will be presenting at the MST Financial Lifesciences & Biotech Forum today at 12:40pm AE D T . Presenting: Marjan Mikel, CEO Time: 12:40pm AEDT on T h ursday 25 November 2021 Investors can register at the following link: https://mstfinancial - au.zoom.us/webinar/register/WN_N9qITyMoTGCMiUuDjyc61w Should you have any questions regarding the forum, please contact Melanie Vandervord at +61 425 211 353 or melanie.vandervord@mstfinancial.com.au - ENDS - For further information, investors and media please contact: Mr Marjan Mikel Mr Nicholas Smedley CEO & Managing Director Executive Chairman Respiri Limited Respiri Limited P: +61 408 462 873 P: +61 447 074 160 E: marjan@respiri.co E: nicholas@respiri.co ™ wheezo is a trademark of Respiri Limited. This ASX announcement dated 2 5 November 202 1 has been authorised for release by the Board of Directors of Respiri Limited. About Respiri Limited Respiri is an e - Health SaaS company supporting respiratory health management. Its world - first technology detects wheeze, a typical symptom of asthma, CO PD and respiratory disease to provide an objective measure of airway limitation. wheezo ® , Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve ast hma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals. Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Austra lia. For additional information about Respiri and its products, please visit www. respiri.co Respiri Limited ¦ ABN 98 009 234 173 ¦ Suite 1, Level 9, 432 St Kida Road, MELBOURE VIC 300 4 ¦ Page | 2 About wheez o Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo - specific weather conditions. The platform has been designe d to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma pat ient. For further information about wheezo , follow the online link https://wheezo.com Forward Looking Statements Certain statements made in this announcement are forward - looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "p lans," "believes," "seeks,” " estimates ” , “guidance” and similar expressions are intended to identify forward looking statements and should be considered an at - risk statement. Such statements are subject to certain risks and uncertainties, particularly thos e risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, u ncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholde rs and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this ann ouncement except as required by law or by any appropriate regulatory authority.

More from Respiri Limited

Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Respiri Limited (ASX:RSH) when you join Listcorp.